ARCHIVES

Drug Discover Groups Recompetition Approved, But Advisors Scale Back Model Development

This article is from The Cancer Letter archive.

Vol. 17 No. 11 | March 15, 1991

Download PDF Visit The Full Archive

Related Articles

Miami Radiotherapy Program Defended

June 30, 1978

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014

FDA Approves Evista for Breast Cancer Risk Reduction.

September 14, 2007

Kimmel Foundation To Donate $1 million for Cancer Research

June 28, 1996

Varmus Confirmation On Fast Track, Nominee Outlines Goals For Next Year

November 12, 1993

M.D. Anderson Closes Trials following FDA Requests for Data

February 16, 1996